KR100531633B1 - Composition comprising the extract of Korean Phellinus linteus for the treatment and protection of cold or flu - Google Patents

Abstract

The present invention relates to a composition containing a domestic Phellinus linteus extract having the ability to suppress influenza virus, and the domestic situation mushroom extract of the present invention inhibits the proliferation of influenza viruses by enhancing the antiviral effect and immune-activating function. As a composition for treating and preventing flu or cold, it can be usefully used for medicines or health foods.

Description

 Composition comprising the extract of Korean Phellinus linteus for the treatment and protection of cold or flu}

The present invention relates to a composition for the treatment and prevention of colds or flu containing domestic situation mushroom extract having influenza virus inhibitory ability.

Common cold is a generic term for acute inflammatory or allergic diseases of the respiratory mucosa, such as the nose, throat, and bronchus. Acute rhinitis, acute pharyngitis, acute laryngitis, acute Tonsillitis, bronchitis, influenza, other viral upper respiratory tract infections, and the like.

The causes of colds are various viruses, bacteria, stimulation of cold and dust, imbalance of body temperature distribution and allergens, but only one of them causes colds. Stimulation of the virus, imbalance of body temperature distribution, and the like have been the main cause of infection by the virus.

There are about 50 kinds of viruses that cause colds, but the main ones are influenza virus, adenovirus, RS virus, and rhinovirus. Typhoid bacteria usually respond to pathogens and symptoms, such as getting typhoid, but it is not always possible to cope with the symptoms of colds and hospital viruses, and because many hospital viruses cause similar cold symptoms, sometimes symptoms cannot be distinguished alone. many. Bacteria, such as Streptococcus, Staphylococcus aureus, Pneumococcal pneumoniae, and influenza bacteria, are often caused by colds, such as in the case of viruses. Bacteria, however, are usually involved in viral infections that are associated with cold complications.

Physical and chemical stimuli such as cold and dust can also cause mild cold symptoms, but stimuli caused by them only return to normal without significant symptoms. A common cold is caused by a temporary anemia of the respiratory mucosa caused by cold or dust stimulation, and the resistance of the part decreases, and the virus begins to infect and become active.

These diseases have a common common cold syndrome such as runny nose, sneezing, cough, fever or sore throat, but they are all called 'cold', but independent diseases such as influenza, allergic rhinitis, etc. Called as In addition, the symptoms are a little unusual, such as acute rhinitis, acute pharyngitis, acute laryngitis, acute tonsillitis, pharyngeal conjunctivitis, bronchitis, etc., tend to be called a disease caused by a painful area. Other viral cold) means.

Flu has a lot in common with the common cold, but there are many differences in complications, so it's good to distinguish. Like flu, Influenza virus (85%), Paraflufluzaza virus, RS virus, and Adenovirus (15%) and other viruses are the main cause.

Currently, the treatment of colds and flu does not cure the underlying virus and is only treating the accompanying symptoms (headache, fever, runny nose, muscle pain, etc.). Influenza, unlike the common cold, is accompanied by severe systemic muscle pain and joint pain, which makes it difficult for normal activities for about a week. Influenza viruses that cause pandemic influenza are classified into three types, A, B, and C, depending on the antigen type, of which A is the most frequent mutation, and is found to account for 90% of the worldwide pandemic viruses. Antigen alterations are proteins that are on the surface of a virus or RNA that contains the genetic information of a virus, causing them to have different traits. They are a survival strategy for survival or evolution.

In recent years, more and more people have been vaccinated against flu. Flu vaccines can tell the World Health Organization (WHO) what types of viruses are common in the region (for example, the Western Pacific region), and then produce vaccines based on them. Each type of virus is notified. In this case, if the vaccine does not match the virus type that was popular at the time, there is a high possibility of getting the flu even if the vaccine is given, so there is a need for a therapeutic agent that can fundamentally suppress the virus.

Sichuan mushrooms, which are known in China since ancient times, are native to the heart of hardwoods such as mulberry, elm, aspen and alder. ( Phellinus Ouel. Em.lmaz ) is a white fungus belonging to. In Korea, the situation mushroom refers to the woody mud mushroom ( Phellinus Linteus ). Situation mushrooms have been used for the treatment of gynecological diseases such as uterine bleeding and menstrual irregularities. Pharmacological and medical studies of the pharmacological action of situational mushrooms have been known to activate immune function in combination with chemotherapy following liver cancer surgery, including gastric cancer, esophageal cancer, duodenal cancer, colon cancer and rectal cancer, which are cancers of the digestive system. . Since the efficacy of the situation mushroom was found to be caused by polysaccharide beta-glucan, research on polysaccharides has been actively conducted. In general, mushrooms contain potassium, calcium, magnesium, vitamins B ₂ , B ₃ , C and fibrous amino acids. In addition to these ingredients, mushrooms contain polysaccharide β-glucan. Beta-glucan reinforces the body's immunity, repels bacteria and foreign substances that have invaded the body, and acts as a suppressor of infection.

As a conventional invention related to a situation mushroom, Korean Patent Application No. 2001-0003264 discloses a Pelinus linteus strain and an anticancer immunoactive polysaccharide isolated and purified therefrom, and Korean Patent Application No. 1998-0015617 discloses a genus of Pelinus genus. Disclosed is a novel separation and purification of a novel polysaccharide that exhibits an immunostimulating activity by mass culturing mycelium or fruiting body from a strain. Korean Patent Registration No. 10-0174433 discloses an anticancer active polysaccharide isolated from Mycelium of Felinus linteus strain, a preparation method thereof, and a pharmaceutical composition comprising the same, and Korean Patent Application No. 2000-0054319 describes The use of a mushroom extract as an anticancer agent is disclosed, and Korean Patent Registration No. 10-0348115 discloses a hair regrowth composition containing a natural situation mushroom extract and a method of preparing the same. In addition, a lot of research on domestic and international medicines and health foods using the situation mushroom and its extracts are being made.

However, not all mushrooms belonging to mud mushrooms have this effect, and to date, it has been found to be wood mud mushrooms, horse mud mushrooms and fir mud mushrooms.

Phellinus genus , an African plant , belongs to the Hymenochaetaceae genus Phellinus and is a mushroom that grows in the hardwoods of the mulberry family, which grow wild in the high alpine areas of Kenya, Africa. The ecological feature of this area is the alpine region of 5000m above sea level, although it is tropical near the equator, it has the best environment for mushroom growth. Perennial, the surface is grayish brown or dark gray, and has a hard shell and smooth. The underside is hollow, light brown, and porous. Spores are small and globose. Each year there is an increase in layers, and the increased layers are clearly distinguished and can be easily counted so that age can be accurately measured. Fruiting bodies are perennial hardwoods. The lampshade is generally horseshoe-shaped, 11 cm high, 20 cm wide, and 8 cm thick. When grown, the upper part is blackened, dark gray, and the surface is rough. When fully grown, the lampshade is tanned and flattened. African situation mushrooms decay live or dead wood, producing white decay in white matter and heartwood.

The medical efficacy of treating diseases is well known in oriental medicine for a long time. It has been shown to have anti-cancer effects and extracts have also been shown to have excellent therapeutic and preventive effects against liver cancer, lung cancer and many other cancers.

Influenza viruses occur worldwide every year, causing respiratory illnesses, which are associated with high mortality in children and the elderly with weak immunity and complications of bronchial diseases such as pneumonia and cardiopulmonary disease. In this case, the mortality rate is higher, which has a big impact on public health.

The pandemic flu virus, which appears worldwide every 10 to 20 years, is particularly deadly, especially the Spanish flu virus, which killed about 20 million people in 1918. It has not occurred since the Hong Kong flu virus in the 60s. In the near future, the emergence of deadly flu virus is expected in the near future.

Influenza viruses can infect the respiratory tract, cause systemic symptoms, change their appearance periodically, and move to other hosts without killing them before they die. Although it is the virus that causes the greatest economic loss to human beings and preventive vaccines have been developed, they have not caught up with the mutation of the virus, and there is no fundamental virus treatment yet.

Accordingly, the present inventors have tested the influenza virus inhibitory ability of fruiting bodies and mycelium extracts and fractions of domestic mushrooms, and completed the present invention by confirming their excellent efficacy.

The present invention is to provide a composition for the prevention and treatment of influenza or cold containing domestic situation mushroom extract and its use as a pharmaceutical and health functional food.

In order to achieve the above object, the present invention provides a composition for the prevention and treatment of colds containing domestic Phellinus linteus extract.

The situation mushroom includes fruiting bodies or mycelium.

The situation mushroom extract is a crude extract or a non-polar solvent soluble extract of fruiting bodies or mycelium, and the crude extract means a lower alcohol such as water, ethanol, methanol, butanol, or a mixed solvent thereof, preferably an extract soluble in water or methanol do.

Hereinafter, the present invention will be described in detail.

The situation mushroom extract of the present invention can be obtained as follows.

First, the domestic mushrooms are collected, washed with water and dried, and then the mushrooms or mycelium are ground and powdered using a homogenizer, and then about 2 to 30 times the dry weight of the mushrooms, preferably about 15 A mixed solvent having a mixing ratio of about 30 to 30 times the volume of water, lower alcohols such as methanol, ethanol and butanol, or about 1: 0.1 to 1:10, preferably methanol to 20 to 100 ° C, preferably Extraction method such as hot water extraction, cold extraction, reflux cooling extraction or ultrasonic extraction for about 0.5 hours to 2 days, preferably 1 hour to 1 day, at an extraction temperature of 70 to 85 ° C., preferably once 5 times, preferably 3 times continuous extraction and filtration under reduced pressure, and the filtrate extract is concentrated under reduced pressure at 20 to 100 ℃, preferably 20 to 70 ℃ by vacuum rotary concentrator, water, lower alcohol or To the mixture of solvent, preferably, it can be obtained as an extract of Phellinus linteus extract soluble in methanol.

The present invention provides a domestic situation mushroom extract effective in the prevention and treatment of the flu or cold obtained by the method.

In addition, the present invention provides a composition effective for the prevention and treatment of flu or cold containing domestic situation mushroom extract of the present invention as an active ingredient.

The composition for the prevention and treatment of influenza or colds containing the domestic situation mushroom extract of the present invention as an active ingredient comprises 0.1 to 80% by weight of the extract, preferably 1.0 to 50% by weight, based on the total weight of the composition.

Pharmaceutical dosage forms of the extracts of the present invention may be used in the form of their pharmaceutically acceptable salts, and may be used alone or in combination with other pharmaceutically active fractions, as well as in any suitable collection.

The composition containing the domestic situation mushroom extract of the present invention may further comprise a suitable carrier, excipient or diluent commonly used in the manufacture of a pharmaceutical composition. Carriers, excipients and diluents that may be included in the composition comprising the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

Compositions comprising extracts according to the invention are each formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories or sterile injectable solutions according to conventional methods. Can be used. Specifically, it may be formulated using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc. that are commonly used when formulated. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose in the extract. ) Or lactose, gelatin and the like can be mixed. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups.In addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.

The amount of domestic situation mushroom extract may vary depending on the age, sex and weight of the patient, but in general, the amount of 0.01 to 500 mg / kg, preferably 0.1 to 100 to 200 mg / kg It can be administered in divided doses. In addition, the dosage of the extract may be increased or decreased depending on the route of administration, the type and severity of the disease, sex, weight, age and the like. Therefore, the above dosage does not limit the scope of the present invention in any aspect.

The composition of the present invention can be administered to mammals such as rats, mice, livestock, humans, etc. by various routes. All modes of administration can be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.

The domestic situation mushroom extract of the present invention has little toxicity and side effects, so it can be used with confidence even when taken for long periods of time.

The present invention provides a health functional food comprising a domestic situation mushroom extract and a food acceptable food supplement additive exhibiting the effects of preventing the flu and cold described above.

Compositions comprising the extracts of the present invention can be used in a variety of food and beverages for the prevention and improvement of the flu, colds. Foods to which the domestic situation mushroom extract of the present invention can be added include various foods, for example, candy, chocolate, beverages, gums, teas, vitamin complexes, health functional foods, and the like, powders, granules, tablets, and capsules. Or in the form of a beverage.

At this time, the amount of the extract in the food or beverage, in the case of the health functional food composition of the present invention can generally be added to 0.01 to 50% by weight, preferably 0.1 to 20% by weight of the total food weight, In the case of 0.02 to 10 g, preferably 0.3 to 1 g, based on 100 ml.

The health functional beverage composition of the present invention is not particularly limited in the liquid component except for containing the extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates, etc. as additional ingredients, as in general beverages. . Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; Conventional sugars such as polysaccharides such as dextrin, cyclodextrin and the like and sugar alcohols such as xylitol, sorbitol, erythritol and the like. The proportion of such natural carbohydrates is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.

Other flavors may be advantageously used natural flavors (tautin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.). The composition of the present invention is a variety of nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid and salts thereof , Organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, etc. Other compositions of the present invention may include natural fruit juices and fruit juice beverages and vegetable beverages. The components may be used independently or in combination The ratio of these additives is not critical but is zero per 100 parts by weight of the composition of the present invention. It is generally selected from the range of about 20 parts by weight.

The present invention is described in more detail based on the following examples and experimental examples, but the present invention is not limited to the examples or experimental examples.

Example 1. Preparation of domestic situation mushroom extract

Domestic situation mushrooms (purchased at Kyungdong Market), take the fruiting body and mycelium, wash it with water and dry it (dry in shaded shade), and then put 200g of the dried mushroom state mycelium and fruiting body into a homogenizer. After finely pulverizing, the mixture was put into a heating mantle, 4 liters of methanol was added, and the extract obtained by repeatedly extracting three times at a predetermined time (12 h) at 79 ° C. was filtered through a rotary pressure reducer. Concentration under reduced pressure using a rotary vacuum evaporator yielded 7 g of mushroom fruit body extract and 7 g of mushroom fungus mycelium extract, respectively.

Experimental Example 1. Determination of antiviral activity of domestic situation mushroom extract

In order to measure the antiviral activity of domestic fruit mushroom body and mycelium extract, MTT screening method was performed to measure the degree of CPE inhibition of virus-infected MDCK cells (Marbin & Darby Canine Kidney) using influenza virus type A / Bayern / 05/97 (H1N1). Measured by.

First, inoculated with MDCK cells (6 × 10 ³ / ml) in 96-well plates and propagated, inoculated in each well with the influenza virus type A / Bavarian virus diluted with DME / 2% FBS culture in 100 CCID ₅₀ ( 50 μl each was inoculated to 50% cell culture inhibiotory dose) and adsorbed at 37 ° C. for 1 hour, and the culture solution was removed. Samples diluted in each concentration (0.00001 ~ 100 ㎍ / ㎖) (domestic situation mushroom fruit body extract and domestic situation mushroom mycelium extract) are added to the well 100ml in each well as a duplicate (duplicate) and 3 in a CO ₂ incubator at 37 ℃ After incubation daily, 0.1 mg of MTT solution was added to all wells, followed by incubation at 37 ° C. for 2 hours. Centrifuge the plate at 450 × g for 5 minutes, remove all but only 30 μl of medium, add 100 μl of DMSO to each well, shake until formazan crystals melt, and then use a microplate reader. The absorbance was measured at 540 nm using a reader).

In order to know the effect of the toxicity of the samples in the drug efficacy evaluation results, the culture medium without the addition of the virus was added to the cells at the time of virus inoculation (mock-infected) and treated with the same method as the cells inoculated with the virus. That is, after one hour of incubation, the medium was removed, the diluted sample was added to the sample, and then incubated for three days, and the number of surviving cells in each well to which the sample was added was compared with the cell control well without the sample. It is shown.

In addition, cytotoxic concentration (CC), effective concentration (EC) and selectivity index (SI) were determined by Equation 1 below.

      CC = O.D / cell control O.D with only sample added

      EC = {(sample and virus added O.D-virus control O.D) / (cell control O.D-virus control O.D)} × 100 (%)

SI = CC / EC

In the following Table 1, the absorbance of the domestic fruit mushroom fruiting body and mycelium extract was higher than the virus control as a whole, and was generally high at the treatment concentration of 0.01 to 100 ㎍ / ㎖.

CC, EC and SI determined by Equation 1 are shown in Table 2 below and FIGS. 1A and 1B. In Figures 1a and 1b, when the general non-toxic concentration is formazan production of 80 to 90%, there was no significant cytotoxicity of domestic situation mushroom fruiting body and mycelium extract. In addition, it was found that the effect was high at a treatment concentration of 0.01 to 100 µg / ml.

Dilution factor Treatment concentration (µg / ml) Absorbance (OD) Virus control Domestic Situation Mushroom (Fruit) Domestic mushrooms (mycelium) 10 ^-1 1000 0.222 0.231 0.291 10 ^-2 100 0.218 0.586 0.607 10 ^-3 10 0.222 0.597 0.618 10 ^-4 One 0.230 0.582 0.645 10 ^-5 0.1 0.227 0.566 0.585 10 ^-6 0.01 0.232 0.589 0.594 10 ^-7 0.001 0.222 0.291 0.605 10 ^-8 0.0001 0.235 0.329 0.414

number Enemy Treatment concentration (µg / ml) CC ^* EC ^** SI ^*** One 10 ^-8 0.0001 72 15 4.701 2 10 ^-7 0.001 67 10 6.931 3 10 ^-6 0.01 67 54 1.256 4 10 ^-5 0.1 63 50 1.257 5 10 ^-4 One 53 53 1.002 6 10 ^-3 10 61 55 1.111 7 10 ^-2 100 69 53 1.293 8 10 ^-1 1000 83 One 112.893  * CC (cytotoxic concentration) ** EC (effective concentration) *** SI (selectivity index)

Experimental Example 2. Determination of the Toxicity of Korean Situation Mushroom Extracts

2-1. Cytotoxicity of Domestic Situary Mushroom Extracts

In order to measure the cytotoxicity of domestic mushroom extracts, the cytotoxicity of the domestic fruit mushroom extracts was measured by MTT assay in the laboratory using MDCK cells (Marbin & Darby Canine Kidney). 1 mg / ml.

First, the cell monolayer (5 × 10 ⁴ cells / ml) was incubated at 37 ° C. overnight, and then the domestic fruit mushroom extract was diluted to each concentration (0.00001 to 100 μg / ml), and the diluted sample was 100 μl. After incubation at 37 ° C. for 3 days, 50 μl of MTT staining was added, incubated at 37 ° C. for 2 hours, then discarded the medium, 150 μl of DMSO was added, and stirred for 1 hour before 540 Absorbance was measured at nm. And the OD value compared to the average of the cell control (PBS) of each extract was compared, and the average of the cell control is represented by a constant line, based on which the higher than this line is not cytotoxic, the lower than this line is determined to be cytotoxic It was.

As a result, as can be seen in Table 3, which shows the cytotoxicity of the domestic mushroom mushroom fruit body extract, no significant cytotoxicity of the domestic mushroom mushroom extract was found.

Dilution factor Treatment concentration (µg / ml) Absorbance (OD)   Cell control Domestic Situation Mushrooms 10 ^-1 1000 0.948 0.730 10 ^-2 100 0.921 0.604 10 ^-3 10 0.833 0.637 10 ^-4 One 0.902 0.618 10 ^-5 0.1 0.926 0.574 10 ^-6 0.01 0.890 0.574 10 ^-7 0.001 0.911 0.585 10 ^-8 0.0001 0.890 0.515

Comparative Experimental Example 1. Comparison of antiviral activity of each situation mushroom extract

In order to compare the antiviral activity of the domestic situation mushroom extract and Cambodian situation mushroom extract of Example 1, by performing the same experiment as the Experimental Example 1 for the domestic situation mushroom fruiting body and Cambodian situation mushroom fruit body Table 4 and FIG. In addition, CC, EC and SI were calculated using Equation 1, and the results are shown in Table 5.

As a result, looking at Table 4, it was found that the absorbance of the domestic situation mushroom fruiting body extract is higher than the Cambodian situation mushroom fruiting body extract.

In addition, as shown in the results of Table 5 and Figure 2, both the domestic mushroom mushroom fruit extract and the Cambodian mushroom mushroom fruit extract did not show a significant cytotoxicity, it was found that the domestic mushrooms in terms of the effect even better.

Dilution factor Treatment concentration (µg / ml) Absorbance (OD) Virus control Domestic Situation Mushrooms   Cambodian Mushrooms 10 ^-1 1000 0.222 0.231 0.252 10 ^-2 100 0.218 0.586 0.249 10 ^-3 10 0.222 0.597 0.237 10 ^-4 One 0.230 0.582 0.239 10 ^-5 0.1 0.227 0.566 0.286 10 ^-6 0.01 0.232 0.589 0.292 10 ^-7 0.001 0.222 0.291 0.238 10 ^-8 0.0001 0.235 0.329 0.287

Dilution factor Treatment concentration (µg / ml) Domestic Situation Mushrooms Cambodian Mushrooms CC ^* EC ^** SI ^*** CC ^* EC ^** SI ^*** 10 ^-1 1000 72 15 4.701 62 9 6.833 10 ^-2 100 67 10 6.931 72 2 40.479 10 ^-3 10 67 54 1.256 71 10 7.280 10 ^-4 One 63 50 1.257 63 9 7.146 10 ^-5 0.1 53 53 1.002 60 2 31.196 10 ^-6 0.01 61 55 1.111 64 2 39.457 10 ^-7 0.001 69 53 1.293 73 3 21.543 10 ^-8 0.0001 83 One 112.893 80 4 20.903  * CC (cytotoxic concentration) ** EC (effective concentration) *** SI (selectivity index)

The domestic situation mushroom extract of the present invention can be administered in the following formulations, the following formulation examples are merely to illustrate the invention, whereby the content of the present invention is not limited.

Formulation Example 1 Preparation of Injection

100 mg of domestic situation mushroom fruiting body extract of Example 1

Sodium Metabisulfite 3.0 mg

Methylparaben 0.8 mg

Propylparaben 0.1 mg

Appropriate sterile distilled water for injection

The above ingredients are mixed and prepared in a conventional manner to have a final volume of 2 ml, and then filled into 2 ml ampoules and sterilized to prepare an injection.

Formulation Example 2 Preparation of Tablet

200 mg of domestic situation mushroom fruiting body extract of Example 1

Lactose 100 mg

Starch 100 mg

Magnesium stearate proper amount

A tablet is prepared by mixing and tableting the above components according to a conventional tablet manufacturing method.

Formulation Example 3 Preparation of Capsule

100 mg of domestic situation mushroom mycelium extract of Example 1

Lactose 50 mg

Starch 50 mg

Talc 2 mg

Magnesium stearate appropriate amount

According to a conventional capsule preparation method, the above ingredients were mixed and filled into gelatin capsules to prepare capsules.

Formulation Example 4 Preparation of Liquid

1000 mg of domestic situation mushroom mycelium extract of Example 1

20 g of sugar

20 g of isomerized sugar

Lemon flavor

Purified water was added to adjust the total volume to 1000 ml. According to the conventional method for preparing a liquid, the above components were mixed, and then filled into a brown bottle and sterilized to prepare a liquid.

Formulation Example 5 Preparation of Healthy Food

1000 mg of domestic situation mushroom fruiting body extract of Example 1

Vitamin mixture proper amount

70 μg of Vitamin A Acetate

Vitamin E 1.0 mg

Vitamin B ₁ 0.13 mg

Vitamin B ₂ 0.15 mg

Vitamin B ₆ 0.5 mg

0.2 μg of vitamin B ₁₂

Vitamin C 10 mg

10 μg biotin

Nicotinic Acid 1.7 mg

Folate 50 ㎍

Calcium Pantothenate 0.5mg

Mineral mixture

Ferrous Sulfate 1.75 mg

Zinc Oxide 0.82 mg

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Dibasic calcium phosphate 55 mg

Potassium Citrate 90 mg

Calcium Carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixtures is mixed with a component suitable for a health food in a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional health food manufacturing method. The granules may be prepared and used for preparing a health food composition according to a conventional method.

Formulation Example 6 Preparation of Healthy Drink

1000 mg of domestic situation mushroom mycelium extract of Example 1

Citric acid 1000 mg

100 g oligosaccharides

Plum concentrate 2 g

1 g of taurine

Add 900 ml of purified water

After mixing the above components in accordance with the conventional healthy beverage manufacturing method, and stirred and heated at 85 L for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and refrigerated Used to prepare the healthy beverage composition of the invention.

The domestic situation mushroom extract of the present invention inhibits the proliferation of influenza virus more prominently by enhancing the antiviral effect and immune activity function than the foreign situation mushroom extract, and thus useful as a pharmaceutical composition for the treatment and prevention of flu or cold Can be used.

Figures 1a and 1b is a measure of the anti-influenza virus activity of domestic situation mushroom extract, Figure 1a is a measure of the anti-influenza virus activity of the domestic situation mushroom fruiting extract, Figure 1b is an anti-influenza virus of the domestic situation mushroom mycelium extract Is a measure of activity,

Figure 2 is a diagram comparing the anti-influenza virus activity of domestic fruit mushroom fruit extract and Cambodian fruit mushroom fruit extract.

Claims (5)

Pharmaceutical composition for the prevention and treatment of flu or cold containing domestic Phellinus linteus extract. The pharmaceutical composition of claim 1, wherein the situation mushroom extract is fruiting body or mycelium. The pharmaceutical composition of claim 1, wherein the situation mushroom extract is extracted with water or methanol. Health functional food for the prevention and improvement of cold comprising the domestic situation mushroom extract of claim 1 and a food supplement acceptable food supplement. The health functional food of Claim 4 which is a health drink.